- Home
- TMO vs AZN Comparison
TMO vs AZN Comparison
Compare TMO & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TMO | AZN |
|---|---|---|
| Founded | 1956 | 1992 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 223.0B | 250.7B |
| IPO Year | 1996 | 1995 |
Fundamental Metrics
Financial Performance| Metric | TMO | AZN |
|---|---|---|
| Price | $658.50 | $168.54 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 18 | 1 |
| Target Price | ★ $636.00 | N/A |
| AVG Volume (30 Days) | 1.7M | ★ 2.9M |
| Earning Date | 04-23-2026 | 04-29-2026 |
| Dividend Yield | 0.40% | ★ 1.73% |
| EPS Growth | ★ 7.32 | N/A |
| EPS | ★ 9.10 | N/A |
| Revenue | ★ $20,918,000,000.00 | N/A |
| Revenue This Year | $6.55 | $10.34 |
| Revenue Next Year | $5.11 | $6.43 |
| P/E Ratio | $72.39 | ★ $31.91 |
| Revenue Growth | ★ 14.47 | N/A |
| 52 Week Low | $435.27 | $72.90 |
| 52 Week High | $663.57 | $212.71 |
Technical Indicators
Market Signals| Indicator | TMO | AZN |
|---|---|---|
| Relative Strength Index (RSI) | 67.14 | 57.68 |
| Support Level | $594.56 | $164.06 |
| Resistance Level | N/A | $170.18 |
| Average True Range (ATR) | 13.17 | 2.78 |
| MACD | 2.67 | 1.00 |
| Stochastic Oscillator | 86.08 | 90.46 |
Price Performance
Historical ComparisonAbout TMO Thermo Fisher Scientific Inc
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year-end 2025 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (the remainder).
About AZN AstraZeneca PLC
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.